Adjuvant treatment of melanoma

Adjuvant treatment of melanoma refers to therapy administered after complete surgical resection of primary cutaneous melanoma in patients at high risk of disease recurrence This clinical setting predominantly encompasses patients with deep, ulcerated primary tumors or regional lymph node involvement, such as resected stage IIB, IIC, III, or oligometastatic stage IV disease Adjuvant systemic interventions aim to eradicate these occult tumor cells to prolong recurrence-free and overall survival

Adjuvant treatment of melanoma refers to therapy administered after complete surgical resection of primary cutaneous melanoma in patients at high risk of disease recurrence This clinical setting predominantly encompasses patients with deep, ulcerated primary tumors or regional lymph node involvement, such as resected stage IIB, IIC, III, or oligometastatic stage IV disease

The defining pathophysiology involves the presumed presence of subclinical micrometastatic disease that persists despite clear surgical margins, which poses a substantial risk for local, regional, or distant systemic relapse

The defining pathophysiology involves the presumed presence of subclinical micrometastatic disease that persists despite clear surgical margins, which poses a substantial risk for local, regional, or distant systemic relapse Adjuvant systemic interventions aim to eradicate these occult tumor cells to prolong recurrence-free and overall survival